NCT03347344View on ClinicalTrials.gov

Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)

PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 17, 2018

Primary Completion Date

December 14, 2020

Study Completion Date

December 14, 2020

Conditions
Spinocerebellar Ataxia Type 2
Interventions
DRUG

Riluzole

50 mg will be administered (per os) twice a day

DRUG

Placebo

50 mg will be administered (per os) twice a day

Trial Locations (1)

75013

Durr, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03347344 - Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL) | Biotech Hunter | Biotech Hunter